Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0MZNRN
ADC Name
ZA202500415A-ADC Example 5
Synonyms
ZA202500415A-ADC Example 5
   Click to Show/Hide
Organization
MYRICX PHARMA LIMITED | IMPERIAL COLLEGE INNOVATIONS LIMITED
Drug Status
Investigative
Drug-to-Antibody Ratio
5
Structure
Antibody Name
Trastuzumab
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
NMT inhibitor 26
  Payload Info 
Therapeutic Target
N-Myristoyltransferase (NMT)
  Target Info 
Linker Name
ZA202500415A-ADC-Example-1-Linker
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.18
uM
CVCL_1661
Breast carcinoma
Half Maximal inhibitory Concentration (lC50) 
2.712
uM
CVCL_0179
Invasive breast carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.18 uM
Method Description
ZR-75-30 Cells were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added at serial dilutions of each test compound spanning a concentration range of either 50 nM to 0.005 nM for the various ADCs. Cell proliferation was measured after 144 hours exposure, by CellTiter-Glo 2.0 Solution Cell Viability Assay.

   Click to Show/Hide
In Vitro Model Breast carcinoma ZR-75-30 cells CVCL_1661
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 2.712 uM Positive her2 expression (her2+++/++)
Method Description
BT-474 cells were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added at serial dilutions of each test compound spanning a concentration range of either 50 nM to 0.005 nM for the various ADCs. Cell proliferation was measured after 144 hours exposure, by CellTiter-Glo 2.0 Solution Cell Viability Assay.

   Click to Show/Hide
In Vitro Model Invasive breast carcinoma BT-474 cells CVCL_0179
References
Ref 1 Antibody drug conjugate comprising NMT inhibitor and its use